Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Carcinoma, Non-Small-Cell Lung 5Unspecified Adult Solid Tumor, Protocol Specific 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Carcinoma, Intraductal, Noninfiltrating 4Breast Carcinoma In Situ 4Brain Neoplasms 4Sarcoma 3Liver Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia 2Gliosarcoma 2Glioblastoma 2

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Radiotherapy 15Lapatinib 15Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Immunohistochemistry 9Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8Biopsy 8exemestane 7Vorinostat 7Magnetic Resonance Spectroscopy 7Letrozole 7Immunoenzyme Techniques 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Goserelin 6Fluorodeoxyglucose F18 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Mass Spectrometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡